Mineralys Therapeutics, Inc. MLYS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $118.5M-32.6% | $132.01M-21.7% | $152.18M+3.0% | $174.71M+50.3% | $175.71M+97.8% | ||
| $53M+106% | $38.6M+62.0% | $31.92M+54.6% | $28.36M+54.9% | $25.78M+58.6% | ||
| $171.5M-14.9% | $170.6M-11.3% | $184.09M+9.4% | $203.07M+51.0% | $201.49M+91.7% | ||
| -$171.5M+14.9% | -$170.6M+11.3% | -$184.09M-9.4% | -$203.07M-51.0% | -$201.49M-91.7% | ||
| $19.71M+51.9% | $15.95M+9.4% | $12.72M-15.8% | $12.3M-17.1% | $12.97M-9.1% | ||
| $19.72M+52.0% | $15.95M+9.3% | $12.73M-15.7% | $12.29M-17.2% | $12.98M-9.2% | ||
| -$151.78M+19.5% | -$154.65M+13.0% | -$171.36M-11.8% | -$190.77M-59.4% | -$188.51M-108% | ||
| -$2.00+46.4% | -$2.32+36.3% | -$2.95+10.3% | -$3.56-30.4% | -$3.73-68.8% | ||
| -$171.45M+14.9% | -$170.55M+11.3% | -$184.03M-9.3% | -$203.01M-50.9% | -$201.44M-91.7% | ||
| -$171.5M+14.9% | -$170.6M+11.3% | -$184.09M-9.4% | -$203.07M-51.0% | -$201.49M-91.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Mineralys Therapeutics, Inc. profitable?
- Mineralys Therapeutics, Inc. is not currently profitable: it reported a net loss of $151.8M over the trailing twelve months.
- What is Mineralys Therapeutics, Inc.'s earnings per share?
- Mineralys Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.00.
- Where does Mineralys Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.